HSAP9 and CUL2 in prostate tissue and adenocarcinoma

Published: 22-02-2021| Version 1 | DOI: 10.17632/6732npdk5y.1


In the present study, we evaluated whether HSPA9 and CUL2 immunoexpression is greater in carcinoma than in non-neoplastic prostate tissue and whether Gleason patterns 3 and 4 increased the risk of Gleason score 6 and 7 (3+4) adenocarcinoma, biochemical persistence (BP), biochemical recurrence (BR), biochemical failure after adjuvant therapy (FB-ADJ), biochemical failure after prostatectomy (FB-PRS), biochemical failure after salvage radiotherapy (FB-RT), biochemical failure after salvage hormone and radiotherapy (FB-HTRT), biochemical failure after salvage therapy (BF-SAL) and systemic disease (SD).


Steps to reproduce

These data are in SPSS v 26 Format